Skip to main content
Caplight Logo









Saku Biosciences

Saku Biosciences

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://www.sakubio.com/

Last Round

Pre Seed

May 18, 2026

Total Funding Raised

$200,000

Company Overview

Saku Biosciences is a biotechnology company that develops high-throughput screening technologies, including its proprietary PicoShell platform, to accelerate strain engineering and improve biomanufacturing economics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

strain engineeringhigh-throughput screeningcell line developmentbiomanufacturingPicoShellsynthetic biologysynbiomicrobial screeninghost cell engineeringbiotech servicescontract research organizationCROfermentation optimizationhydrogel encapsulationbioprocess development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Saku Biosciences Comparables

Compare Saku Biosciences with similar companies based on industry and business-model similarity.

Saku Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Partillion Bioscience Corporation
75%
Manus Bio
69%
Ginkgo Bioworks
65%

Saku Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedMay 18, 2026

Key People

Founding team and executive leadership

Mark van Zee

Co-founder and CEO

Founding Team

Saku Biosciences Investors

Notable investors and investment history

Saku Biosciences investors
InvestorRounds
Capital FactoryAccelerator
UCLA Anderson Venture AcceleratorAccelerator
Big Idea VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2024

    Grew 200% QoQ from 2 to 6 employees.

  • Oct 6, 2024

    Grew 100% QoQ from 3 to 6 employees.

Saku Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Saku Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Saku Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range8
Year Founded2024
Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?